APA (7th ed.) Citation

Viale, G., Regan, M. M., Dell'Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., . . . Coates, A. S. (2011). Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of Oncology, 22(10), 2201.

Chicago Style (17th ed.) Citation

Viale, G., et al. "Which Patients Benefit Most from Adjuvant Aromatase Inhibitors? Results Using a Composite Measure of Prognostic Risk in the BIG 1-98 Randomized Trial." Annals of Oncology 22, no. 10 (2011): 2201.

MLA (9th ed.) Citation

Viale, G., et al. "Which Patients Benefit Most from Adjuvant Aromatase Inhibitors? Results Using a Composite Measure of Prognostic Risk in the BIG 1-98 Randomized Trial." Annals of Oncology, vol. 22, no. 10, 2011, p. 2201.